Introduction
============

Venous thrombosis is defined as a blood clot (thrombus) forming in a vein or in multiple veins. Classically, venous thromboembolism (VTE) incorporates two clinical entities: deep vein thrombosis (DVT) and pulmonary embolism. The causes of VTE can be categorized into two groups of hypercoagulable states (also referred to as thrombophilia): hereditary or acquired, according to its etiology. In the clinical settings, it is more useful to categorize VTE into idiopathic (a term equivalent to unprovoked) and provoked types. In provoked VTE, there is an obvious precedent risk factor for thrombosis. Patients with unprovoked VTE, who are subsequently diagnosed with a malignancy usually within a year of follow-up, are retrospectively regarded as having overt cancer-associated VTE. Although unprovoked VTE is a diagnosis made at the initial presentation of venous thrombosis when no obvious etiology is discovered, in the real world, any unprovoked VTE that precedes a malignancy can be retrospectively categorized as an overt cancer-associated type, regardless of the length of the follow-up interval.

The causes of inherited thrombophilia, which is a lifelong genetic predisposition to thrombosis, are markedly different between the Western and the Asian patients. In a small study of 50 Taiwanese adult patients with sonogram-proved VTE, protein S deficiency was the most common cause of hereditary VTE.[@b1-cmar-9-751] The most common causes of hereditary VTE in Western countries are factor V Leiden (FVL; FV R506Q), which is associated with activated protein C resistance, and factor II G20210A polymorphism, both of which are extremely rare in Asian populations.[@b2-cmar-9-751]

Provoked-type VTE can result from an obvious preceding event, such as surgery (particularly orthopedic surgery), endoscopic submucosal dissection for superficial gastric neoplasm,[@b3-cmar-9-751] trauma, pregnancy, presence of an indwelling central venous catheter, immobilization, or neoadjuvant (pre-operative) chemotherapy.[@b4-cmar-9-751]--[@b8-cmar-9-751] It is noteworthy that several VTE patients have more than one provoking risk factor; a clear example would be immobilization after orthopedic surgery with an indwelling central venous catheter.[@b9-cmar-9-751]--[@b14-cmar-9-751] Idiopathic or unprovoked VTE is the focus of this study. This is mainly because clinicians should maintain a high index of suspicion of occult cancer, practically defined in epidemiologic studies as cancer developing within 1 year after the diagnosis of unexplained VTE, which is the underlying etiology.

VTE has been considered rarer in East Asian populations than in Caucasians.[@b14-cmar-9-751]--[@b19-cmar-9-751] White et al[@b20-cmar-9-751] utilized the California Discharge Data Set to identify a cohort of incident VTE patients in 1996. After adjusting for the misclassification of race, investigators calculated VTE incidence to be highest in African-Americans, with 141 per 100,000, followed by 104 per 100,000 in Caucasians; 55 per 100,000 in Hispanics; and 21 per 100,000 in Asian/Pacific Islanders. Idiopathic VTE incidence was significantly lower among both Hispanics and Asian/Pacific Islanders than among Caucasians or African-Americans (*p* \< 0.001).[@b21-cmar-9-751]

Several epidemiologic studies of VTE have been conducted in the past decade in East Asian patients.[@b16-cmar-9-751]--[@b18-cmar-9-751] An evidence-based analytic approach with data synthesis is required to improve our knowledge of issues related to the bidirectional relationship regarding incidence rate (IR) or risks such as relative risk (RR) or hazard ratio (HR) from VTE to cancer development and from cancer diagnosis to an episode of VTE in East Asian patients.

Materials and methods
=====================

Ethical statement
-----------------

This study is an expert review of the current published epidemiologic studies on the bidirectional relationship between VTE and cancer, and thus was classified as research exempt from review by the institutional review board of the Kuang Tien General Hospital.

Literature search
-----------------

Peer-reviewed clinical reports in the English language indexed in PubMed were included. Two explicit statements of questions being addressed with reference to participants, interventions, comparisons, outcomes, type of question, and study design were established as follows:[@b22-cmar-9-751] the first explicit foreground question of cancer risk from an episode of VTE: patients (P), adult East Asian patients; exposure (E), patients who developed VTE; comparison (C), comparators without VTE; outcomes (O), risk of cancer development (IR, RR, or HR); type of question (T), prognosis-type question; and study design (S), population-based longitudinal studies. The second question of risk of VTE development from cancer was as follows: P, adult East Asian patients; E, patients who have cancer; C, comparators without cancer; O, risk of VTE development (IR, RR, or HR); T, prognosis-type question; and S, population-based longitudinal studies.

A comprehensive literature search strategy was established with the following details to search the PubMed literature database using medical subject headings (MeSHs) and qualified Boolean search terms: "Venous Thrombosis"\[MeSH\] AND "Neoplasms"\[MeSH\] AND "Taiwan"\[MeSH\] OR "Taiwan"\[All Fields\], the results revealed 50 articles, of which three qualified articles were selected; "Venous Thrombosis"\[MeSH\] AND (population-based\[All Fields\] AND study\[All Fields\]) OR cohort\[All Fields\]) AND ("Taiwan"\[MeSH\] OR "Taiwan"\[All Fields\]), the results revealed 41 articles, but none were selected; and ("Venous Thromboembolism"\[MeSH\] OR ("Venous"\[All Fields\] AND "Thromboembolism"\[All Fields\]) OR "Venous Thromboembolism"\[All Fields\]) AND ("Taiwan"\[MeSH\] OR "Taiwan"\[All Fields\]), the results revealed 97 articles, of which nine were qualified to be reviewed. Using a similar search strategy, the search terms were then extended from Taiwan to Korea, Japan, China, and finally to East Asia. Similar literature search strategy with no regard to countries or geographical regions was employed for selecting the comparator studies conducted in non-Asian or mixed populations.

Statistical analysis
--------------------

Proportional meta-analysis was performed to derive a pooled proportion of the development of incident cancer in VTE patients. The method adopted was Stuart-Ord (inverse double arcsine square root).[@b23-cmar-9-751] Noncombinability of studies was examined with the decision to choose either fixed or random effects based upon *I*^2^.[@b24-cmar-9-751] We used the StatsDirect software (<http://www.statsdirect.com>, England: StatsDirect Ltd., 2017) to perform all pooled meta-analyses.

Results and discussion
======================

Estimation of VTE incidence in the East Asian population
--------------------------------------------------------

VTE incidence of any etiology is much less in the East Asian population than in Caucasians.

Combining the data for VTE incidence from Taiwanese, Korean, and Hong Kong Chinese studies[@b16-cmar-9-751]--[@b18-cmar-9-751] using proportional meta-analysis with the random-effects model (because *I*^2^ = 76.2%) showed that the pooled proportion was 20.3 (95% CI, 11.2--32) per 100,000 person-years ([Figure 1](#f1-cmar-9-751){ref-type="fig"}).[@b25-cmar-9-751] This pooled East Asian IR estimation is approximately one-tenth to one-sixth of that in the community-based Framingham Heart Study, which is 203 (95% CI, 179--226) per 100,000 person-years. Comparing the present current East Asian estimation with the result of another relevant epidemiological study conducted in Auckland, New Zealand, in an ethnically diverse population, the age-adjusted annual rate of VTE per 100,000 person-years in all Asian populations (including India, and South East Asia) in New Zealand was estimated at 25.3, which is within the 95% CI of the results of the current study.[@b26-cmar-9-751] In the Auckland study, people of European descent had a fourfold increased risk of VTE (RR = 4.02; 95% CI, 3.34--4.84) compared with those of Asian descent.[@b26-cmar-9-751]

A retrospective population-based study in Taiwan by Lee et al[@b18-cmar-9-751] has shown that in women VTE incidence per 100,000 person-years markedly increased from 2.0 events in those aged \<30 years to 118.2 in those aged \>80 years; similarly, in men, the incidence increased from 3.0 events in those aged \<30 years to 83.1 in those aged \>80 years. The recurrence rate of VTE is estimated at 5.1% per person-year.[@b18-cmar-9-751]

Newly diagnosed VTE incidence is estimated at approximately 4,400 new cases each year in Taiwan and 7,100 (13.8 per 100,000 per annum times a population of 51.25 million) in South Korea. The crude incidence of VTE in Taiwanese patients steadily increases with age, ranging from 4 per 100,000 in patients aged \<40 years to 108 in those aged ≥80 years.[@b18-cmar-9-751]

[Table 1](#t1-cmar-9-751){ref-type="table"} compares estimated IRs of overall and unprovoked VTE in the general population in five Asia--Pacific (including four East Asian) and two Western countries. Unprovoked (idiopathic) VTE accounts for approximately 34% (95% CI, 19.8%--50.6%; random-effects model using DerSimonian--Laird methods) of all cases of VTE in East Asia.[@b14-cmar-9-751],[@b18-cmar-9-751],[@b19-cmar-9-751] These are synthetic data constructed after the author performed a proportional meta-analysis using a random-effects model after pooling three relevant studies.

To calculate the proportion of unprovoked VTE among the entire cohort of patients with VTE, it is appropriate to combine data from four studies.[@b14-cmar-9-751],[@b18-cmar-9-751],[@b19-cmar-9-751],[@b26-cmar-9-751] A proportional meta-analysis with a random-effects model under an *I*^2^ of 99.8% derived a pooled proportion of 35% with a 95% CI of 24%--48% ([Table 1](#t1-cmar-9-751){ref-type="table"}, [Figure 2](#f2-cmar-9-751){ref-type="fig"}).

There is an interesting observation that there is seasonal variation in VTE occurrence among Korean patients, regardless of whether it is unprovoked or non-cancer associated. Jang et al[@b27-cmar-9-751] have reported in their series of 1,495 VTE patients that VTE incidence peaked in December and was the lowest in July (χ^2^ = 11.83, *p* = 0.008). This difference in VTE incidence between winter and summer in East Asia provides a new perspective on VTE prevention strategy, particularly in regions where seasons can bring sharp changes in the ambient temperature. Winter is associated with a decreased mobility.

Risk of occult cancer in East Asian patients with unprovoked VTE
----------------------------------------------------------------

A prospective trial conducted in Canada (854 patients with unprovoked VTE) provided reliable data on the incidence of occult cancer during a 1-year follow-up period, which was 3.9 per 100 patient-years.[@b28-cmar-9-751] The Tromso survey of 733 Norwegians found that the incidence of occult cancer after VTE was 5.5 per 100 patient-years during a 1-year follow-up.[@b29-cmar-9-751] The IR of cancer in Taiwanese patients with unprovoked VTE was estimated at 2.2--4.5 per 100 patient-years ([Table 2](#t2-cmar-9-751){ref-type="table"}).[@b10-cmar-9-751],[@b30-cmar-9-751]

Population-based observation studies sometimes come up with interesting study results. In a population-based study with 2-year follow-up conducted in Taiwan, the study results imply that the risk of occult cancer is higher in older patients with VTE than young patients. Compared with patients aged below 40 years, those aged ≥65 years with unprovoked VTE had a nearly sixfold increased risk of subsequent cancer development.[@b10-cmar-9-751] Among patients with unprovoked VTE, 7% of them would receive a diagnosis of cancer within 2 years after the first idiopathic VTE episode. The three most common cancers after unprovoked VTE in Taiwanese patients were lung, liver, and colorectal cancers, with rates of 18.3%, 12.3%, and 10.9%, respectively.[@b30-cmar-9-751]

Risk of VTE in East Asian patients with all-site malignancy and by specific site
--------------------------------------------------------------------------------

Cancer induces a hypercoagulable state.[@b12-cmar-9-751] The risk of cancer-associated thrombosis is determined by patient-related factors, such as the state of hypercoagulability; medical comorbidities; ambulation; prior personal history of venous thrombosis; tumor-related factors, such as cancer type, early versus advanced stage, extent of disease, and tumor grade; cancer-derived circulating tissue factor-containing microvesicles;[@b31-cmar-9-751],[@b32-cmar-9-751] and treatment-emergent causes, including surgery, chemotherapy, antiangiogenic agent use, and hormonal treatment. The discussion of cancer-associated procoagulants, such as tissue factors that are present in blood or tissue, is beyond the scope of this study. According to their tendency to develop venous thrombosis, cancers can be categorized as having high, medium, or low thrombotic risk. Cancers originating in the chest and abdomen are particularly associated with high absolute rates of VTE.[@b33-cmar-9-751]

A retrospective population-based study of 83,203 cancer patients at unspecified sites found an IR of VTE of 13.9 per 1,000 patient-years (95% CI, 13.4--14.4), representing an adjusted HR of 4.7 (95% CI, 4.5--4.9), compared with patients without cancer.[@b33-cmar-9-751] The risk of VTE in cancer patients is markedly decreased in East Asians; two recent Taiwanese studies found IRs of 1.9 and 3.4 per 1,000 person-years ([Table 3](#t3-cmar-9-751){ref-type="table"}).[@b9-cmar-9-751],[@b34-cmar-9-751]

[Table 4](#t4-cmar-9-751){ref-type="table"} shows VTE incidence in East Asian patients with various types of cancer reported in epidemiologic studies published after 2010. The risk is commonly represented as the cumulative IR (CIR) of VTE. Yokoyama et al[@b35-cmar-9-751] have reported a CIR of 11% in a single-institution observational study of patients with newly diagnosed diffuse large B-cell lymphoma. Lee et al[@b36-cmar-9-751] have reported a 2-year CIR of 9.2% in Korean patients with pancreatic adenocarcinoma. A prospective cohort study of patients with newly diagnosed lymphoma across Asia found a 1-year actuarial incidence of 7.9%.[@b37-cmar-9-751] Lee et al[@b38-cmar-9-751] have found a 2-year CIR of 6.6% in a single-institution observational study of Korean patients with non-small-cell lung cancer. A retrospective population-based cohort study conducted in 1,013 Taiwanese patients with uterine cervix cancer found a 5-year CIR of 3.3%.[@b39-cmar-9-751] Ye et al,[@b40-cmar-9-751] in a single-institution observational study of gynecological cancer patients in China, have reported a 10-year CIR of 2% for the entire cohort, 3.7% for vulvar cancer, and 2.5% for ovarian cancer. Kang et al,[@b41-cmar-9-751] in a single-institution study of inoperable gastric cancer patients in Korea, have found a 1-year CIR of 3.5%.

To determine whether there is a similar pattern in the occurrence of VTE in specific cancer types that are more common in the Asian population, it will be worthwhile for this study to perform a head-to-head comparison of studies between East Asian and Western countries using esophageal cancer and the stomach cancer as examples ([Table 5](#t5-cmar-9-751){ref-type="table"}). The incidence of VTE in East Asian patients with esophageal cancer is quite similar to those reported in the Western countries.[@b4-cmar-9-751],[@b5-cmar-9-751],[@b7-cmar-9-751],[@b42-cmar-9-751] However, in stomach cancer, the risk of VTE is lower in East Asians with advanced cancer.[@b41-cmar-9-751],[@b43-cmar-9-751],[@b44-cmar-9-751] For advanced stomach cancer, the 1-year cumulative incidence is 9% in the American patients as reported by Fuentes et al.[@b45-cmar-9-751] A Denmark study demonstrates that perioperative chemotherapy administered in the group of patients with gastric cancer will raise the incidence of VTE to 37%.[@b7-cmar-9-751] In contrast, a South Korean prospective database research shows that the 2-year cumulative incidence in patients with metastatic stage IV gastric cancer is 24.4%.[@b44-cmar-9-751] Another Japanese study on advanced-stage gastric cancer treated with palliative chemotherapy reveals that the 1-year cumulative incidence of VTE is 13.6%, much lower than those reported in Western countries.[@b43-cmar-9-751] The difference in the occurrence pattern may be site specific or resulted from different working definitions of VTE adopted in different studies.

Upper extremity DVT, although much less common, is more related to malignancy and thrombophilia than is lower extremity DVT. In a population-based thrombophilia study involving a total of 1,203 VTE patients in Malmö, Sweden, 63 (5.2%) had upper extremity DVT.[@b46-cmar-9-751] At diagnosis, 30% of the patients with upper extremity DVT had active malignancy, and thrombophilia accounted for 29% of the patients with upper extremity VTE. Among the patients with thrombophilia, 66% were heterozygous and 17% were homozygous for the FVL mutation, 10% were heterozygous for the prothrombin mutation, and 6% were both heterozygous for the FVL mutation and had lupus anticoagulant antibodies.[@b46-cmar-9-751]

A brief discussion on thrombophilia is warranted to understand the scope of the problems. An earlier Japanese study reported that 8 (2%) of 392 otherwise healthy subjects had protein S deficiency and two (0.5%) had protein C deficiency.[@b47-cmar-9-751] Compared with the Japanese results, Zhu et al[@b2-cmar-9-751] have reported much lower frequencies of genetic deficiency in the three main natural anticoagulants -- antithrombin, protein C, and protein S -- which are rare in Western countries but are important risk factors for VTE in Asian countries. This cross-sectional survey aiming to establish sex- and age-related normal ranges for activity levels of the three main natural anticoagulants in 3,493 healthy Han Chinese patients found that 15 (4.3 per 1,000) harbored a genetic variant detected by direct sequencing.[@b2-cmar-9-751]

Conclusion
==========

Recent population-based cohort studies conducted in East Asia have provided an opportunity for us to understand the bidirectional relationship of VTE and cancer in the region. The IR of VTE of any etiology in East Asians is much less than in Caucasians. Combining the data for VTE incidence in the general population from Taiwanese, Korean, and Hong Kong Chinese studies using proportional meta-analysis revealed that the pooled proportion was 20.3 (95% CI, 11.2--32) per 100,000 person-years. Newly diagnosed VTE incidence is estimated at least 4,400 new cases each year in Taiwan and 7,100 in South Korea, because it is hard to pick up cases of silent VTE in retrospective cohort studies. Unprovoked VTE accounts for approximately 34% (95% CI, 19.8%--50.6%) of all cases of VTE in East Asia. The IR of cancer in Taiwanese patients with unprovoked VTE was estimated at 2.2--4.5 per 100 patient-years. Similar to the trend in general population, the risk of VTE in cancer patients is markedly lessened in East Asians than in Caucasians, with an IR of 1.9--3.4 per 1,000 person-years in the region.

The implications of the findings reported in this paper are as follows: knowledge translation can be realized by extracting published results from relevant epidemiological research. Second, robust estimation derived from the statistical synthesis gives a clearer picture of the bidirectional risk of VTE and cancer in East Asia. Last but not least, future research can be more efficient via deepening the regional collaboration to establish an international prospective data collection.
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![Proportional meta-analysis synthesizing the IR of VTE in three East Asian studies to derive a combined result.\
**Note:** A random-effects model was used with *I*^2^ = 76.2%.\
**Abbreviations:** CI, confidence interval; IR, incidence rate; VTE, venous thromboembolism.](cmar-9-751Fig1){#f1-cmar-9-751}

![Meta-analysis of the proportion of unprovoked VTE pooling four relevant epidemiologic studies with a random-effects model with *I*^2^ = 99.7% gives a pooled proportion of 35% (95% CI, 24%--48%).\
**Abbreviations:** CI, confidence interval; VTE, venous thromboembolism.](cmar-9-751Fig2){#f2-cmar-9-751}

###### 

Estimated IR of overall and unprovoked VTE in the general population compared between five Asia-Pacific and two Western studies

                                    Martinez et al[@b19-cmar-9-751]/2014                                                               Puurunen et al[@b14-cmar-9-751]/2016     Liao et al[@b26-cmar-9-751]/2014                                                                           Lee et al[@b18-cmar-9-751]/2010        Jang et al[@b16-cmar-9-751]/2011       Cheuk et al[@b15-cmar-9-751]/2004                     Law et al[@b17-cmar-9-751]/2016
  --------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------- ---------------------------------------------------------------------------------------------------------- -------------------------------------- -------------------------------------- ----------------------------------------------------- -------------------------------------------------------
  **Study design**                  Retrospective population-based study                                                               Community-based Framingham Heart Study   Retrospective population-based study                                                                       Retrospective population-based study   Retrospective population-based study   Retrospective population-based study                  Retrospective population-based study
  **Country**                       UK                                                                                                 USA                                      New Zealand                                                                                                Taiwan                                 Korea                                  Hong Kong                                             Hong Kong
  **Incident VTE**                  35,373                                                                                             297                                      2,096                                                                                                      5,347                                  NR                                     NR                                                    NR
  **Incident unprovoked VTE**       16,708 (47%)                                                                                       29%                                      797 (38%)                                                                                                  1,465 (27.4%)                          NR                                     NR                                                    NR
  **IR per 100,000 person-years**   Overall, 131.5 (95% CI, 130.2--132.9); excluding cancer-associated, 107.0 (95% CI, 105.8--108.2)   203 (95% CI, 179--226)                   European: 101.7; all Asian: 25.3 (both age-adjusted). RR (European/all Asian): 4.02 (95% CI, 3.34--4.84)   15.9 (4.4 for unprovoked VTE)          13.8 (overall)                         21 (including provoked and cancer-associated cases)   31.7 (including provoked and cancer-associated cases)

**Abbreviations:** CI, confidence interval; IR, incidence rate; NR, not reported; RR, relative risk; VTE, venous thromboembolism.

###### 

Epidemiologic studies showing the incidence of cancer in patients with VTE

                           Sun et al[@b30-cmar-9-751]/2016               Chung et al[@b10-cmar-9-751]/2014                       Gran et al[@b29-cmar-9-751]/2017   Carrier et al[@b28-cmar-9-751]/2015
  ------------------------ --------------------------------------------- ------------------------------------------------------- ---------------------------------- -------------------------------------------------------
  **Study design**         Retrospective population-based cohort study   Retrospective population-based cohort study             Tromso survey                      Multicenter, open-label, randomized, controlled trial
  **Country**              Taiwan                                        Taiwan                                                  Norway                             Canada
  **Patient number**       27,751                                        28,243                                                  733                                854
  **Site of VTE**          Unprovoked; nonspecific site                  Unprovoked; nonspecific site                            Unspecified                        Unprovoked
  **Follow-up duration**   Median 4.18 years (range, 0.003--13)          First 2 years of follow-up                              1 year following a VTE             1 year following a VTE
  **Incident cancer**      2,886                                         1,944                                                   40 (=occult cancer)                33 (=occult cancer)
  **IR of cancer**         2.2/100 patient-years                         4.5/100 patient-years                                   5.5/100 patient-years              3.9/100 patient-years
  **Risk**                 aHR = 2.26 (versus non-VTE)                   aHR = 5.57 in aged ≥65 years (versus aged \<20 years)   NR                                 NR
  **95% CI**               2.16--2.37                                    3.15--9.82                                              NR                                 NR

**Note:** In contrast, Carrier et al's[@b28-cmar-9-751] prospective clinical trial data are also extracted for direct comparison.

**Abbreviations:** aHR, adjusted hazard ratio; CI, confidence interval; IR, incidence rate; NR, not reported; VTE, venous thromboembolism.

###### 

Epidemiologic studies showing the incidence of VTE in patients with cancer

                                         Chew et al[@b9-cmar-9-751]/2015           Yu et al[@b34-cmar-9-751]/2012         Walker et al[@b33-cmar-9-751]/2013
  -------------------------------------- ----------------------------------------- -------------------------------------- --------------------------------------------
  **Study design**                       Retrospective population-based study      Retrospective population-based study   Retrospective population-based study
  **Country**                            Taiwan                                    Taiwan                                 UK
  **Patient number**                     43,855                                    497,180                                83,203
  **Cancer type**                        All sites                                 All sites                              All sites
  **Follow-up duration**                 \>2 years                                 Median 21.3 years                      NR
  **Incident VTE**                       473 (validated with treatment received)   5,296                                  3,352
  **IR of VTE per 1,000 person-years**   3.4                                       1.9                                    13.9 (95% CI, 13.4--14.4)
  **Risk**                               NR                                        NR                                     aHR = 4.7 compared with general population
  **95% CI**                             NR                                        NR                                     4.5--4.9

**Abbreviations:** aHR, adjusted hazard ratio; CI, confidence interval; IR, incidence rate; NR, not reported; VTE, venous thromboembolism.

###### 

Epidemiologic studies published after 2010 showing the incidence of VTE in East Asian patients with various types of cancer

  Reference                              Cancer type                Study design                            Location   Patient no.   Observation period   Incident VTE   CIR of VTE
  -------------------------------------- -------------------------- --------------------------------------- ---------- ------------- -------------------- -------------- -----------------------------------------------
  Lee et al[@b36-cmar-9-751]/2016        Pancreas                   Retrospective population-based cohort   Korea      1,115         2 years              132            2-year CIR = 9.2%
  Park et al[@b37-cmar-9-751]/2012       Newly diagnosed lymphoma   Prospective cohort                      Asia       686           21.8 months          54             1-year actuarial incidence = 7.9%
  Lee et al[@b38-cmar-9-751]/2014        NSCLC                      Single institute                        Korea      1,998         2 years              131            2-year CIR = 6.6%
  Tsai et al[@b39-cmar-9-751]/2012       Uterine cervix             Retrospective population-based cohort   Taiwan     1,013         5 years              33             5-year CIR = 3.3%
  Ye et al[@b40-cmar-9-751]/2015         Gynecologic                Single institute                        China      7,562         10 years             155            10-year CIR = 2.0%; vulvar 3.7%; ovarian 2.5%
  Kang et al[@b41-cmar-9-751]/2012       Inoperable gastric         Single institute                        Korea      3,095         1 year               108            1-year CIR = 3.5%
  Yokoyama et al[@b35-cmar-9-751]/2012   Newly diagnosed DLBCL      Single institute                        Japan      142           4.5 years            15             11%

**Abbreviations:** CIR, cumulative incidence rate; DLBCL, diffuse large B-cell lymphoma; NSCLC, non-small-cell lung cancer; VTE, venous thromboembolism.

###### 

Head-to-head comparison of studies conducted in the East Asian or Western countries on the risk of VTE in gastric and esophageal cancers which are more common in the Asian population

  Cancer type                           Reference                            Country                                                                          Patient number                                                              Follow-up period                                                                          Risk of VTE
  ------------------------------------- ------------------------------------ -------------------------------------------------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ---------------
  Stomach cancer                        Rollins et al[@b8-cmar-9-751]/2011   UK                                                                               N = 44 (25% received neoadjuvant chemotherapy; 18% adjuvant chemotherapy)   NER                                                                                       7.1%
  Fuentes et al[@b45-cmar-9-751]/2017   USA                                  N = 112 (adenocarcinoma \[84%\] and advanced disease \[59%\])                    Median 21.3 (IQR 8.9--42.4) months                                          1-year cumulative incidence = 9%                                                          
  Larsen et al[@b7-cmar-9-751]/2015     Denmark                              N = 27 (perioperative chemotherapy with oxaliplatin, epirubicin, capecitabine)   NER                                                                         10/27 (37%)                                                                               
  Lee et al[@b44-cmar-9-751]/2010       South Korea                          N = 2,085 (prospective database research)                                        2 years                                                                     2-year cumulative incidences = stages I (0.5%), II--IV (M0) (3.5%), and IV (M1) (24.4%)   
  Kang et al[@b41-cmar-9-751]/2012      South Korea                          N = 3,095 (inoperable advanced gastric cancer)                                   1 year                                                                      1-year cumulative incidence = 3.5%                                                        
  Arai et al[@b43-cmar-9-751]/2017      Japan                                N = 283 (all advanced stage; before or during palliative chemotherapy)           1 year                                                                      1-year cumulative incidence = 13.6%                                                       
  Esophageal cancer                     Bosch et al[@b5-cmar-9-751]/2014     The Netherlands                                                                  N = 226 (surgery alone)                                                     NER                                                                                       9/226 = 3.98%
  Bosch et al[@b5-cmar-9-751]/2014      The Netherlands                      N = 110 (neoadjuvant CRT: 41.4 Gy with paclitaxel--carboplatin)                  NER                                                                         12/110 = 10.9%                                                                            
  Berger et al[@b4-cmar-9-751]/2005     USA                                  N = 131 (neoadjuvant CRT)                                                        NER                                                                         11/131 = 8.4%                                                                             
  Larsen et al[@b7-cmar-9-751]/2015     Denmark                              N = 43 (with perioperative chemotherapy)                                         NER                                                                         3/43 = 7.0%                                                                               
  Kato et al[@b42-cmar-9-751]/2016      Japan                                N = 153 (neoadjuvant chemotherapy)                                               NER                                                                         21/153 = 13.7%                                                                            

**Abbreviations:** CRT, chemoradiotherapy; IQR, interquartile range; M0, no distant metastasis; M1, at least one distant metastasis; NER, not explicitly reported; VTE, venous thromboembolism.
